GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (NAS:PRTK) » Definitions » 3-Year FCF Growth Rate

Paratek Pharmaceuticals (Paratek Pharmaceuticals) 3-Year FCF Growth Rate : 32.20% (As of Jun. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Paratek Pharmaceuticals 3-Year FCF Growth Rate?

Paratek Pharmaceuticals's Free Cash Flow per Share for the three months ended in Jun. 2023 was $-0.03.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 32.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 19.00% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 17.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Paratek Pharmaceuticals was 79.60% per year. The lowest was -15.20% per year. And the median was 18.15% per year.


Competitive Comparison of Paratek Pharmaceuticals's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Paratek Pharmaceuticals's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paratek Pharmaceuticals's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's 3-Year FCF Growth Rate falls into.



Paratek Pharmaceuticals 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Paratek Pharmaceuticals  (NAS:PRTK) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Paratek Pharmaceuticals 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Paratek Pharmaceuticals (Paratek Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.
Executives
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jeffrey Stein director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Thomas John Dietz director C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Evan Loh director, officer: CEO 75 KNEELAND STREET, BOSTON MA 02111
William M. Haskel officer: CLO, General Counsel & Sec. ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Adam Woodrow officer: President & Chief Commercial C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON MA 02111
Randall B. Brenner officer: Chief Development & Regulatory C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON MA 02116
Robert S Radie director 101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355
Rolf K Hoffmann director LORBEERWEG 7, WEGGIS V8 CH-6353
Michael Bigham director, officer: Exec. Chairman of the Board 890 WINTER STREET, WALTHAM MA 02451
James D Dondero 10 percent owner 300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Douglas W. Pagan officer: Chief Financial Officer 75 KNEELAND STREET, BOSTON MA 02111
Omega Fund Iv, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199

Paratek Pharmaceuticals (Paratek Pharmaceuticals) Headlines

From GuruFocus